Monthly Monitoring of Plasma NfL in Treated Relapsing-remitting Multiple Sclerosis to Detect Persistent Infraclinical Disease Activity

Abroad (travel likely)Recruiting

Conditions

Multiple Sclerosis (MS) - Relapsing-remitting

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

CHU de Nice, Nice, France
Contact: Study coordinator (Christine LEBRUN FRENAY, Pr.) · lebrun-frenay.c@chu-nice.fr
CHU de Nîmes, Nîmes, France
Contact: Study coordinator (Anissa Megzari) · drc@chu-nimes.fr · 04.66.68.42.36

Study leads

Eric Thouvenot
Principal Investigator
Centre Hospitalier Universitaire de Nīmes

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Assessing Changes in Multi-parametric MRI in MS Patients Taking Clemastine Fumarate as a Myelin Repair Therapy

Multiple Sclerosis (MS) · Multiple Sclerosis, Relapsing-Remitting · Multiple Sclerosis, Primary Progressive

Abroad (travel likely)RecruitingPHASE1, PHASE2

San Francisco, United States

Safety and Efficacy Study of Fingolimod in Taiwanese Adults (≥ 20years) With Relapsing Remitting Multiple Sclerosis

Multiple Sclerosis

Abroad (travel likely)RecruitingPHASE4

Kaohsiung City, Taiwan · Taichung, Taiwan

Hyperpolarized Carbon Metabolic Imaging in Multiple Sclerosis

Multiple Sclerosis · RRMS · Relapsing Remitting MS

Abroad (travel likely)RecruitingPHASE2

San Francisco, United States

Exploration of Novel Imaging Biomarkers on OCT for Ublituximab Treatment Response in Multiple Sclerosis

Multiple Sclerosis (MS) - Relapsing-remitting

Abroad (travel likely)Recruiting

Baltimore, United States